New drug combo aims to shrink pancreatic tumors before surgery
NCT ID NCT07415525
First seen Feb 22, 2026 · Last updated Apr 29, 2026 · Updated 9 times
Summary
This study tests a new drug (IBI343) combined with chemotherapy given before surgery for people with a specific type of pancreatic cancer that is on the edge of being removable. The goal is to shrink the tumor enough to allow successful surgery and improve long-term outcomes. About 40 participants will receive 4 cycles of the drug combo, then surgery if possible, followed by more chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Zhejiang University Schlool of Medicine, Hangzhou, Zhejiang
Hangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.